Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has dosed its first patients in the pivotal Phase 3 clinical trial of lead drug candidate EMD-RX5. This marks an important milestone in the development of EMD-RX5 as the first potential over-the-counter (OTC) treatment for the symptoms of psychological distress.
Emyria welcomes dosing of first patient in Phase 3 anxiety trial
